FENNEC PHARMACEUTICALS INC.
About FENNEC PHARMACEUTICALS INC.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $44.6M
- Net income
- -$9.7M
- Total assets
- $70.6M
- Market cap
- $302.2M
- Operating margin
- -14.1%
- Net margin
- -21.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $44.6M
- Operating expenses
- $50.9M
- Operating income
- -$6.3M
- Income tax
- $106.0K
- Net income
- -$9.7M
- EPS (basic)
- $-0.34
- EPS (diluted)
- $-0.34
Balance sheet
- Total assets
- $70.6M
- Current assets
- $67.0M
- Total liabilities
- $35.1M
- Current liabilities
- $10.5M
- Shareholders’ equity
- $35.5M
Cash flow
- Operating cash flow
- -$12.5M
- Investing cash flow
- -$10.2M
- Financing cash flow
- $22.6M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $302.2M
- EPS (diluted)
- $-0.34
- Shares outstanding
- 34.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 28, 2002
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $9.7M in FY2025.
- Trading 11% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review FENNEC PHARMACEUTICALS INC..
Write a review
News about FENNEC PHARMACEUTICALS INC.
News & sentiment via Polygon.io
